Week In Review: BioAtla And Pfizer In $1 Billion Oncology Drug Deal
December 12, 2015 at 13:07 PM EST
BioAtla's $1 billion payout, which includes Pfizer's rights to the CTLA4 antibodies, is a combination of up-front, regulatory and sales milestone payments plus tiered royalties on potential revenues.